First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with broad potential as a novel treatment for muscle-sparing weight loss Study led by Associate Professor Morten Hostrup, a leading authority on β2-adrenergic receptor signaling in skeletal muscle at the University of Copenhagen, to evaluate muscle […]
Prof. Carl D. Regillo, MD, presented clinical data from the Phase 1b trial evaluating Breye Therapeutics’ lead candidate, danegaptide, in 24 patients with non-proliferative diabetic retinopathy (NPDR) with associated macular edema Oral treatment was well tolerated, showed signs of clinical effect and retinal imaging data consistent with reductions in vascular leakage, one of the core […]
Marketing executive brings 20+ years of global diabetes experience to support European scale-up and next-generation Kaleido launch readiness Utrecht, the Netherlands — January 29, 2026 ViCentra, a European medical device company commercializing the Kaleido insulin patch pump system, announced today that Reman McDonagh, PhD, has joined the Company as Vice President, Global Marketing. McDonagh’s appointment […]
Secures an additional $13 million, bringing the total to $98 million with new investments from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech, plus increased support from Innovation Industries Strengthens manufacturing scale-up and commercial operations in Germany, the Netherlands, and France, and advances U.S. market preparation Validates ViCentra’s strategy and team, […]
Karen Baxter, former VP & GM at Dexcom with deep expertise in diabetes device commercialization across Europe, joins as SVP Sales, Europe Jay Little, leader from Medtronic Diabetes, appointed VP Strategy & Business Development Team expansion will drive growth strategy, market development, and partnerships for scalable expansion to accelerate Kaleido’s growth across European markets Utrecht, […]
